CSV April 3, 2023 through April 3, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DICLOFENAC	IDENTIFICATIO	*USPNF 2021*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM	N/*C.*	*ISSUE 1*						*solution*: Change 7 N hydrochloride acid to: 7 N hydrochloric acid
?197? SPECTROSCOPIC IDENTIFICATION TESTS	INTRODUCTION AND SCOPE	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Change (see *Mid-Infrared Spectroscopy* ?854?, *Ultraviolet-Visible Spectroscopy* ?857?, *X-Ray Powder Diffraction* ?941?, *Near-Infrared Spectroscopy—Theory and Practice* ?1856?, and *Raman Spectroscopy* ?858?. to: (see *Mid-Infrared Spectroscopy*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?854?, *Near-Infrared Spectroscopy* ?856?, *Ultraviolet-Visible Spectroscopy* ?857?, *Raman Spectroscopy* ?858?, and *X-Ray Powder Diffraction* ?941?).
?1051? CLEANING GLASS APPARATUS	CLEANING VALIDATION BEST PRACTICES	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Table 2*: Change and verify levels are below *Loss on Drying* ?731?. to: and verify levels are below limit of detection.
?643? TOTAL ORGANIC CARBON	PROCEDURES	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *1. Bulk Water/1.10 System suitability*: Change r_E = 100 × [(*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_C/r_L$) to: $r_E = 100 \times (r_C/r_L)$
TACROLIMUS	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *USP Tacrolimus Related Compound A RS*: Change 792.01 to: 792.02 AND In *USP Tacrolimus 8-epimer RS*: Change 804.02 to: 804.03
CETIRIZINE HYDROCHLORIDE	IMPURITIES/*Residue on Ignition* ?281?	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Delete Sample: 1 g
SPECTROSCOPIC IDENTIFICATION TESTS	NEAR-INFRARED AND RAMAN SPECTROSCOPY	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Change (see *Near-Infrared Spectroscopy—Theory and Practice* ?1856?), to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(see ?856?), AND Change (see *Chemometrics* ?1039?, *Near-Infrared Spectroscopy—Theory and Practice* ?1856?, and *Raman Spectroscopy—Theory and Practice* ?1858?, and the following chapters to be published at a later date: *Near-Infrared Spectroscopy—Theory and Practice* ?1856? and *Raman Spectroscopy—Theory and Practice* ?1858?). to: (see *Chemometrics* ?1039?, *Near-Infrared Spectro*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								scopy—Theory and Practice ?1856?, and *Raman Spectroscopy—Theory and Practice* ?1858?).
QUETIAPINE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*/*System Suitability*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Resolution*: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks; *System suitability solution* to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks; *System suitability solution*
DIMENHYDRINATE INJECTION	*Assay*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Change *Solution A, Solution B, Mobile phase, Internal*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution, and *Chromatographic system*—Prepare as directed in the *Assay* under *Dimenhydrinate Tablets*. to: *Solution A*—Dissolve 0.8 g of ammonium bicarbonate in 800 mL of water. Add 200 mL of methanol, filter, and degas. *Solution B*—Dissolve 0.8 g of ammonium bicarbonate in 150 mL of water. Add 850 mL of methanol, filter, and degas. *Mobile phase*—Use variable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under *Chromatography* ?621?). *Internal standard solution* —Prepare a solution in methanol containing 2.0 mg of 2-hydroxy benzyl alcohol per mL. AND Add *Chromatographic system* (see *Chromatography* ?621?)— The liquid chromatograph is equipped with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a 229-nm detector and a 4.6-mm × 25-cm column that contains packing L7. The flow rate is about 1.5 mL per minute. The chromatograph is programmed as follows. Time (minutes), 0, 0–7.0, 7.0–7.1, 7.1–15, 15–15.1, 15.1–22.0 Solution A (%), 100, 100, 100?0, 0, 0?100, 100 Solution B (%), 0, 0, 0?100, 100, 100?0, 0 Elution, equilibration, isocratic, linear gradient, isocratic, linear gradient,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								isocratic Chromatograph the *Standard preparation*, and record the peak areas as directed for *Procedure*: the relative retention times are about 0.3 for 8-chlorotheophylline, 0.5 for the internal standard, and 1.0 for diphenhydramine; the resolution, *R*, between 8-chlorotheophylline and the internal standard is not less than 4.5; and the relative standard deviation for replicate injections is not more than 2.0%.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Change *Procedure*—Proceed as directed for *Procedure* in the *Assay* under *Dimenhydrinate Tablets*. Calculate the quantity, in mg, of dimenhydrinate ($C_{17}H_{21}NO \cdot C_7H_7ClN_4O_2$) in each mL of the Injection taken by the formula: $(200C/V)(R_U/R_S)$ in which C is the concentration of USP Dimenhydrinate RS in the *Standard preparation*; V is the volume, in mL, of Injection taken; and the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								other terms are as defined therein. to: *Procedure*— Separately inject equal volumes (about 10 ?L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of dimenhydrinate ($C_{17}H_{21}NO \cdot C_7H_7ClN_4O_2$) in each mL of the Injection taken by the formula: (200*C*/*V*)(*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$ /R_S) in which *C* is the concentration of USP Dimenhydrinate RS in the *Standard preparation*; *V* is the volume, in mL, of Injection taken; and R_U and R_S are the peak area ratios of diphenhydramine to the internal standard obtained from the *Assay preparation* and the *Standard preparation*, respectively.
ALCOHOLOMETRIC TABLE	INTRODUCTION	*USPNF 2021 ISSUE 3*	Online	27-Aug-2021	1-Dec-2021	*NA*	*NA*	Change Similarly, a specific gravity value of 0.8092 in column *1* corresponds to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a solution that contains 95% alcohol by weight or 92.42% alcohol v/v. to: Similarly, a specific gravity value of 0.8092 in column *1* corresponds to a solution that contains 95% alcohol v/v or 92.42% alcohol by weight.
LUMEFANTRINE	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Change (±)-2,7-Dichloro-9-[(Z)-*p*-chlorobenzylidine]-?[(dibutylamino)methyl]-fluorene-4-methanol to: (±)-2,7-Dichloro-9-[(Z)-*p*-chlorobenzylidene]-?-[(dibutylamino)methyl]-flu

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								orene-4-methanol
ZIPRASIDONE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	4699	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Ziprasidone Related Compound F RS: Change 2-(2-Amino-5-{2-[4-(benzo[*d*]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetic acid. $C_{21}H_{23}ClN_4O_2S$ 430.95 to: Sodium 2-(2-amino-5-{2-[4-(benzisothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate; Also known as Sodium 2-(2-amino-5-{2-[4-(benzo[*d*]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophe

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								nyl)acetate monohydrate. $C_{21}H_{22}ClN_4NaO_2S \cdot H_2O$ 470.95
PRODUCTS FOR NEBULIZATION—CHARACTERIZATION TESTS	AERODYNAMIC ASSESSMENT OF NEBULIZED AEROSOLS	*USP43–NF38*	8407	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Change Apparatus 5 (see general chapter *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* ?601?), a cascade impactor, has been calibrated at 15 L/min specifically to meet the recommendation of the CEN Standard and is therefore used for this test.[3] to: The Next Generation

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Impactor without pre-separator used with inhalation aerosols, inhalation sprays, and nasal aerosols is described in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* ?601?. An archival version of this cascade impactor has been calibrated at 15 L/min specifically to meet the recommendation of the CEN Standard and this configuration is therefore used for this test.[3]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Apparatus*: Change A detailed description of Apparatus 5 and the induction port is contained in ?601?, and includes details of to: *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* <601>, *C.4 Next Generation Impactor without Pre-separator for Inhalation Aerosols, Inhalation Sprays, and Nasal Aerosols*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								includes details of AND In *Procedure*: Change *Figure 2. Apparatus 5 for Measuring the Size Distribution of Products for Nebulization.* to: *Figure 2. Next Generation Impactor without Pre-separator for Measuring the Size Distribution of Products for Nebulization.* AND In *Procedure*: Change on the back-up filter as described for Apparatus 5 (see ?601?). to: on the back-up

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								filter as described in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests <601>, C.4 Next Generation Impactor without Pre-separator for Inhalation Aerosols, Inhalation Sprays, and Nasal Aerosols*. AND In *Procedure*: Change Determine the cumulative mass-weighted particle-size distribution of the aerosol size-fractionated by the impactor in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accordance with the procedure given in ?601?. to: Determine the cumulative mass-weighted particle-size distribution of the aerosol size-fractionated by the impactor in accordance with the procedure given in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* <601>, *C.4 Next Generation Impactor without Pre-separator for Inhalation Aerosols, Inhalation*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sprays, and Nasal Aerosols. AND In *Table 2*: Change *Table 2. Cut-off Sizes for Apparatus 5 at 15 L/min* to: *Table 2. Cut-off Sizes for Next Generation Impactor without Pre-separator at 15 L/min*
MYCOPHENOLATE MOFETIL TABLETS	PERFORMANCE TESTS/ *Dissolution* <711>	*USP43–NF38*	3049	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Test 3*/*Analysis*: Change Result = $(r_U/r_S) \times C_S \times D$ r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* *C*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								S= concentration of the *Standard solution* (mg/mL) D = dilution factor of the *Sample solution*, 50 to: Result = $(A_U/A_S) \times C_S \times D$ A_U = absorbance from the *Sample solution* A_S = absorbance from the *Standard solution* C_S = concentration of the *Standard solution* (mg/mL) D = dilution factor of the *Sample solution*, 50
GEMCITABINE	IM	*USP43–NF38*	2094	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Table 2*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR INJECTION	PUR ITIES/*Organic Impurities*							Change Cytosine[a] to: Cytosine AND Delete footnote a AND Update footnote order
Zinc Acetate	REAGENTS AND REFERENCE TABL ES/*Reagent Specifications*	*USP43–NF38*	6219	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Change [557-34-6]. to: [5970-45-6].
GEMCITABINE HYDROCHLOR IDE	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	2093	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Table 2*: Change Cytosine[a] to: Cytosine AND Delete footnote a AND Update footnote order
QUAZEPAM	ADDITIONAL R EQUIREMENT S/*USP Reference*	*USP43–NF38*	3790	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Quazepam Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	standards <11>							RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-one.
PRODUCTS FOR NEBULIZATION—CHARACTERIZATION TESTS	AERODYNAMIC ASSESSMENT OF NEBULIZED AEROSOLS	*USP43–NF38*	8407	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Please see the updated *Figure 2* at online.uspnf.com
CODEINE PHOSPHATE TABLETS	*Identification*	*USP43–NF38*	1139	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *A*.: Change Render the filtrate alkaline with 6 N ammonium hydroxide, extract with several small portions of chloroform, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								proceed as directed in *Identification* test *A* under *Codeine Phosphate Injection*, beginning with “Evaporate the combined chloroform extracts.” The specified results are observed. to: Render the filtrate alkaline with 6 N ammonium hydroxide and extract with several small portions of chloroform. Evaporate the combined chloroform extracts on a steam bath to dryness, and dry at 80° for 4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hours: the IR absorption spectrum of a potassium bromide dispersion of the residue so obtained exhibits maxima at the same wavelengths as that of the codeine obtained by similarly treating 1 mL of a solution of USP Codeine Phosphate RS (1 in 100).
GEMCITABINE FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2094	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Cytosine RS: Change 2(1*H*)-Pyrimidinone, 4-amino-. to: Cytosine.
DORZOLAMIDE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP*	*USP43–NF38*	1496	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Dorzolamide Hydrochloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							Related Compound A RS: Change 360.91 to 360.89
ONDANSETRON INJECTION	*Assay*	*USP43–NF38*	3265	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Chromatographic system*: Change The liquid chromatograph is equipped with a 216-nm detector and a 4.6-mm × 20-cm column that contains packing L10. to: The liquid chromatograph is equipped with a 216-nm detector and a 4.6-mm × 25-cm column that contains packing L10.
GEMCITABINE HYDROCHLOR	ADDITIONAL REQUIREMENT	*USP43–NF38*	2093	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Cytosine RS:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE	S/*USP Reference Standards <11>*							Change 2(1*H*)-Pyrimidinone, 4-amino-. to: Cytosine.
QUAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference standards <11>*	*USP43–NF38*	3791	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Quazepam Related Compound A RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-one.
CODEINE PHOSPHATE TABLETS	*Limit of morphine*	*USP43–NF38*	1139	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Change A 1-mL portion of the filtrate from *Identification* test *B* meets the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								requirements of the test for *Limit of morphine* under *Codeine Phosphate*. to: Dissolve about 50 mg of potassium ferricyanide in 10 mL of water, and add 1 drop of ferric chloride TS and a 1-mL portion of the filtrate from *Identification* test *B*: no blue color is produced immediately.
CLOZAPINE	IM PUR ITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In *Table 2*: Change Demethyl clozapin to: Demethyl clozapine
DACTINOMYCIN	CHEMICAL INFORMATION	*USP43–NF38*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Please see the updated chemical

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								structure at online.uspnf.com
AMIODARONE HYDROCHLORIDE INJECTION	IMPURITIES/*Limit of Iodide*	*USP43–NF38*	254	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In *Potassium iodate solution*: Change 10.7 g/L of potassium iodide in water to: 10.7 g/L of potassium iodate in water
AMITRIPTYLINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	263	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP References Standards <11>*	*Revision Bulletin (Official May 01, 2021)*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Benazepril Related Compound B RS: Change (3*S*) 3-[[(1*R*) 1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-1-benzazepine-1-acetic acid, monohydrochloride; Also known as 2-[(*SR*)-3-{[(*RS*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride. to: 2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*S*)-3-[[(1*R*)-1-(Ethoxycarb

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride.
KETOROLAC TROMETHAMINE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2513	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Change *Mobile phase, Diluent, System suitability solution, Standard solution,* and *Sample solution*: Proceed as directed in the *Assay*. to: *Mobile phase, Diluent, System suitability solution, Standard solution, Sample solution*, and *System suitability*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BENAZEPRIL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP References standards <11>*	*USP43–NF38*	488	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Proceed as directed in the *Assay*. In USP Benazepril Related Compound A RS: Change (3*R*) 3-[[(1*R*) 1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride. to: 2-[(*R*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*R*)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride. AND In USP Benazepril Related Compound B RS: Change (3*S*) 3-[[(1*R*) 1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride. to: 2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-o

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								xo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*S*)-3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride. AND In USP Benazepril Related Compound C RS: Change 3-(1-Carboxy-3-phenyl-1(*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-1-(3*S*)-benzazepine-1-acetic acid. to: (*S*)-2-{[(*S*)-1-(Carboxymethyl)-2-oxo-2,3, *H*-benzo[*b*]azepin-3-yl]amino}-4-phenylbutanoic acid; Also known as 3-(1-Carboxy-3-phenyl-1(*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. AND In USP Benazepril Related Compound D

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS: Change (3-(1-Ethoxycarbonyl-3-cyclohexyl-(1*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid, monohydrochloride. to: 2-[(*S*)-3-{[(*S*)-4-Cyclohexyl-1-ethoxy-1-oxobutan-2-yl]amino}-2-oxo-2,3,4,5-tetra hydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3-(1-Ethoxycarbonyl-3-cyclohexyl-(1*S*)-propyl)amino-2,3,4,5-tetrahyd

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid, monohydrochloride. AND In USP Benazepril Related Compound ERS: Change 3-Amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. to: (*S*)-2-(3-Amino-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl)acetic acid hydrochloride; Also known as 3-Amino-2,3,4,5-tetrahydro-2-ox

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-1*H*-1-(3*S*)-benzazepine-1 -acetic acid mo nohydrochloride . $C_{12}H_{14}N_2O_3$ · HCl 270.71 AND In USP Benazepril Related Compound F RS: Change *tert* -Butyl-3-amino- 2,3,4,5-tetrahyd ro-2- oxo-1*H* -1-(3*S*)-benzazepine-1 -acetic acid. to: *tert*-Butyl (*S*)-2-(3-amino-2- oxo-2,3,4,5-tetr ahydro -1*H* -benzo[*b*]azepin-1-yl)ace tate;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Also known as *tert*-Butyl-3-amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. $C_{16}H_{22}N_2O_3$ 290.36 AND In USP Benazepril Related Compound G RS: Change (3-(1-Ethoxycarbonyl-3-phenyl-(1*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid ethyl ester. to: Ethyl (*S*)-2-{[(*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-1-(2-ethoxy-2-oxoethyl)-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-3-yl]amino}-4-phenylbutanoate; Also known as (3-(1-Ethoxycarb
								S)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid ethyl ester. $C_{26}H_{32}N_2O_5$ 452.55
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official March 01, 2021)*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In *Test 14/Analysis*: Delete $Result_4 = \{(C_4 \times V) + [(C_3 + C_2 + C_1) \times V_S]\} \times (1/L) \times 100$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LANSOPRAZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2551	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Lansoprazole Related Compound B RS: Change 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl] methyl]sulfanyl]-1*H*-benzimidazole. $C_{16}H_{14}F_3N_3OS$ 353.36 to: 2-{[(3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl]thio}benzimidazole monohydrate. $C_{16}H_{14}F_3N_3OS \cdot H_2O$ 371.38
GLYBURIDE	CHEMICAL INFORMATION	*USP43–NF38*	2125	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Change 1-[[*p*-[2-(5-Chloro-*o*-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 1-[[*p* -[2 -(5-C hloro-*o* -anisamido)ethy l]phenyl]sulfonyl]-3-cyclohexylur ea
NORTRIPTYLI NE HYDROCH LORIDE	ADDITIONAL R EQUIREMENT S/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43
BENAZEPRIL HYDROCHLORI DE TABLETS	ADDITIONAL R EQUIREMENT S/*USP References Standards <11>*	*USP43–NF38*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Benazepril Related Compound B RS: Change (3*S*)-3-[[(1*R*)-1-(Ethoxycarb onyl)-3-phenylpr opyl]amino]-2,3, 4,5-tetrahydro-2 -oxo-1*H* -1-benzazepine- 1-acetic acid, m

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onohydrochloride; Also known as 2-[(*SR*)-3-{[(*RS*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride. to: 2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*S*)-3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride.
AMITRIPTYLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS	ASSAY/*Procedure*	*USP43–NF38*	938	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change 313.86 to: 313.87
GARLIC FLUID EXTRACT	COMPOSITION/*Content of S-Allyl-L-cysteine*	*USP43–NF38*	5023	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of *S*-allyl-L-cysteine ($C_6H_{11}SN$) in the portion of Fluidextract taken: to: Calculate the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								percentage of *S*-allyl-L-cysteine in the portion of Fluidextract taken:
HYDROXYZINE PAMOATE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2269	28-May-2021	1-Jun-2021	*NA*	*NA*	In *System suitability/Suitability requirements/Resolution*: Change 4-chlorobenophenone to: 4-chlorobenzophenone
CARBOMER HOMOPOLYMER	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Please see the updated chemical structure at https://online.uspnf.com
GADOTERATE MEGLUMINE INJECTION	OTHER COMPONENTS/*Content of Meglumine*	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Result = (*a*/*?*) × (1/*l*) × (1/*L*) × 100 to: Result = (*a*/*?*) × 100 × (1/*l*) × (1/*L*) × 100

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBOMER COPOLYMER	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Limit of Ethyl Acetate and Cyclohexane/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* AND In *Limit of Benzene/Analysis*: Change *Samples*: *Standard stock solution, Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution A, Standard solution B, Standard solution C, and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution*
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	938	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change 313.86 to: 313.87
BIFIDOBACTERIUM LONGUM SUBSP. LONGUM	DEFINITION	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Change *Bifidobacterium longum* subsp. *longum* comprises to: *Bifidobacterium longum* subsp. *longum* comprises
AMITRIPTYLIN	CHEMICAL	*USP43–NF38*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E HYDROCHLORIDE	INFORMATION							313.86 to: 313.87
CARBOMER IN TERPOLYMER	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Limit of Ethyl Acetate and Cyclohexane/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* AND In *Limit of Benzene/Analysis*: Change *Samples:*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard stock solution, *Standard solution A*, *Standard solution B*, *Standard solution C*, and *Sample solution* to: *Samples: Standard solution A*, *Standard solution B*, *Standard solution C*, and *Sample solution*
MINOXIDIL TABLETS	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$

Pagination

- First page « First
- Previous page ‹ Previous
- …

- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- …
- Next page Next ›
- Last page Last »